Clinical Trial Update: Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating liposomal doxorubicin for persistent or recurrent cervical cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Cancer | Phase 2 | Status: TERMINATED